Trulieve Cannabis
Vertically integrated medical-cannabis cultivator, manufacturer, and dispensary operator.
Something off on this page? Send us feedback.
Profile
Produces medical-cannabis flower, extracts, and finished products, earning most revenue through branded dispensaries while also serving selected wholesale channels. Its vertically integrated, medical-only operation spans Florida, Pennsylvania, West Virginia, and Georgia.
Operates a vertically integrated medical-cannabis business that cultivates, processes, and manufactures cannabis products, then sells them primarily through branded dispensaries. Its portfolio spans flower, extracts, and finished products across premium, core, and value labels, with online reservations, a mobile app, and a rewards program extending the retail channel.
Runs a medical-only consolidated footprint across Florida, Pennsylvania, West Virginia, and Georgia, with Florida and Pennsylvania as cornerstone markets. Cultivation, production, retail, and selective wholesale are organized through Southeast and Northeast hubs; Georgia also supplies approved products to independent pharmacies. Maintaining state licenses and federal DEA registrations is essential, while most retail footprint is in Florida.
Company facts
Key statistics
Year to date +35.8% · Average volume (30d) 951.4K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | $0.09 | −$2.11 | −2,544.1% | $268.5M | $271.0M | +0.9% | +3.77% |
| Aug 6, 2026Q2 FY26 | $0.06 | −$2.11 | −3,616.7% | $268.5M | $271.0M | +0.9% | +6.64% |
| May 7, 2026Q1 FY26 | −$0.01 | $0.01 | +170.8% | $284.7M | $286.8M | +0.7% | −5.48% |
| Feb 26, 2026Q4 FY25 | −$0.07 | −$0.22 | −196.2% | $298.3M | $293.1M | −1.7% | −1.69% |
Financial highlights
| 5 quarters | — | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | $302.1M | $288.2M | $293.1M | $286.8M | $271.0M | |
| Gross profit | — | $182.9M | $169.9M | $175.2M | $170.1M | $162.3M | |
| Operating income | — | $52.4M | $41.4M | $19.4M | $35.4M | −$370.5M | |
| Net income | — | −$13.8M | −$26.8M | −$42.9M | $2.4M | −$406.1M | |
| Diluted EPS | — | −$0.07 | −$0.14 | −$0.22 | $0.01 | −$2.10 | |
| Gross margin | — | 60.6% | 58.9% | 59.8% | 59.3% | 59.9% | |
| Operating margin | — | 17.3% | 14.4% | 6.6% | 12.4% | -136.7% |
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $325.4M · Total debt $577.3M · Total assets $2.08B · Shareholders' equity $767.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 169.90M · Float 162.36M
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| AdvisorShares Trust | 10.64M | 6.26% | 13G | Jul 8, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Colgate-Palmolive
Florida medical retail and Pennsylvania branded-cannabis competitor.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Trulieve Cannabis | $11.76 | −0.46% | $2.01B | — | 25.6 | 1.7 | −10.3% |
| Colgate-Palmolive | $90.85 | +0.15% | $72.62B | 36.0 | 23.1 | 3.5 | +4.9% |
| Median | 36.0 | 23.1 | 3.5 | +4.9% |